Paratek appoints Molnar and Loh to senior positions

Thursday, May 24, 2012 09:00 AM

Paratek Pharmaceuticals of Boston, Mass., has named Dennis Molnar as director, president and CEO, and Evan Loh, MD, as chief medical officer and chairman of the board of directors.  

Molnar, formerly Paratek's vice president of corporate development, has 19 years of experience in the pharmaceutical and biotechnology industries, working in a variety of capacities, including business development, management, finance and consulting. Before joining Paratek in 2001, he served as president of JBI Associates, a software and consulting firm providing services to hospital pharmacies.  Molnar has also served as director of finance and business development at Magainin Pharmaceuticals.  

Loh comes to Paratek from Pfizer where he served as senior vice president of development and strategic operations, worldwide R&D. Prior to joining Pfizer in 2009, Loh was vice president of clinical R&D at Wyeth, where he had global responsibility for scientific, strategic and operational leadership of clinical development efforts across multiple therapeutic areas.  Loh is the 2006 recipient of the Heroes of Chemistry award from the American Chemical Society for his leadership role at Wyeth in the clinical development of Tygacil, a novel glycylcycline broad-spectrum antibiotic. Loh has served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs